Type 1 diabetes, metabolic syndrome and cardiovascular risk

Juan J. Chillarón, Juana A. Flores Le-Roux, David Benaiges, Juan Pedro-Botet

Research output: Contribution to journalReview articleResearchpeer-review

104 Citations (Scopus)

Abstract

Patients with type 1 diabetes mellitus (T1DM) traditionally had a low body mass index and microangiopathic complications were common, while macroangiopathy and the metabolic syndrome were exceptional. The Diabetes Control and Complications Trial, published in 1993, demonstrated that therapy aimed at maintaining HbA1c levels as close to normal as feasible reduced the incidence of microangiopathy. Since then, the use of intensive insulin therapy to optimize metabolic control became generalized. Improved glycemic control resulted in a lower incidence of microangiopathy; however, its side effects included a higher rate of severe hypoglycemia and increased weight gain. Approximately 50% of patients with T1DM are currently obese or overweight, and between 8% and 40% meet the metabolic syndrome criteria. The components of the metabolic syndrome and insulin resistance have been linked to chronic T1DM complications, and cardiovascular disease is now the leading cause of death in these patients. Therefore, new therapeutic strategies are required in T1DM subjects, not only to intensively lower glycemia, but to control all associated metabolic syndrome traits. © 2014 Elsevier Inc.
Original languageEnglish
Pages (from-to)181-187
JournalMetabolism: Clinical and Experimental
Volume63
Issue number2
DOIs
Publication statusPublished - 1 Feb 2014

Keywords

  • Cardiovascular risk
  • Chronic complications
  • Metabolic syndrome
  • Type 1 diabetes

Fingerprint

Dive into the research topics of 'Type 1 diabetes, metabolic syndrome and cardiovascular risk'. Together they form a unique fingerprint.

Cite this